Atom | Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Due Dates: November 18, 2025 (New) | November 18, 2026 (Renewal/Resubmission/Revision) | November 18, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $300,000 direct costs per year, for up to 5 years; NIH anticipates up to 4 awards, subject to appropriations.

Summary: Supports basic research to understand and mitigate the acute and delayed harmful effects of ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations.

Key Information: Clinical trials are not allowed; applications must focus on DHS-designated opioids and not on pain management or SUD treatment.

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Sign in to see full grant listing